tradingkey.logo
搜尋

Alamar Biosciences Ord Shs

ALMR
添加自選
20.590USD
+0.150+0.73%
收盤 06/01, 16:00美東報價延遲15分鐘
1.42B總市值
--本益比TTM

Alamar Biosciences Ord Shs

20.590
+0.150+0.73%

關於 Alamar Biosciences Ord Shs 公司

Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.

Alamar Biosciences Ord Shs簡介

公司代碼ALMR
公司名稱Alamar Biosciences Inc
上市日期Apr 17, 2026
CEOLuo (Yuling)
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址47071 Bayside Pkwy
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94538
電話15106269888
網址https://alamarbio.com
公司代碼ALMR
上市日期Apr 17, 2026
CEOLuo (Yuling)

Alamar Biosciences Ord Shs公司高管

名稱
名稱/職務
職務
持股
持股變動
,
,
--
--
Mr. Yuling Luo, Ph.D.
Mr. Yuling Luo, Ph.D.
Founder, Chairman of the Board, Chief Executive Officer
Founder, Chairman of the Board, Chief Executive Officer
--
--
Mr. Timothy (Tod) White, J.D.
Mr. Timothy (Tod) White, J.D.
President
President
--
--
Mr. Shiping (Steve) Chen, Ph.D.
Mr. Shiping (Steve) Chen, Ph.D.
Founder, Chief Operating Officer, Director
Founder, Chief Operating Officer, Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Justin Mcanear
Mr. Justin Mcanear
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Independent Director
Independent Director
--
--
Dr. Nicholas J. Naclerio, Ph.D.
Dr. Nicholas J. Naclerio, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ian W. Ratcliffe
Mr. Ian W. Ratcliffe
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
,
,
--
--
Mr. Yuling Luo, Ph.D.
Mr. Yuling Luo, Ph.D.
Founder, Chairman of the Board, Chief Executive Officer
Founder, Chairman of the Board, Chief Executive Officer
--
--
Mr. Timothy (Tod) White, J.D.
Mr. Timothy (Tod) White, J.D.
President
President
--
--
Mr. Shiping (Steve) Chen, Ph.D.
Mr. Shiping (Steve) Chen, Ph.D.
Founder, Chief Operating Officer, Director
Founder, Chief Operating Officer, Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Justin Mcanear
Mr. Justin Mcanear
Chief Financial Officer
Chief Financial Officer
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 4月22日 週三
更新時間: 4月22日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Qiming Venture Partners
15.29%
Luo (Yuling Ph.D.)
9.68%
Illumina Innovation Funds
9.18%
Sherpa Healthcare Partners
6.92%
Sands Capital Ventures LLC
6.10%
其他
52.83%
持股股東
持股股東
佔比
Qiming Venture Partners
15.29%
Luo (Yuling Ph.D.)
9.68%
Illumina Innovation Funds
9.18%
Sherpa Healthcare Partners
6.92%
Sands Capital Ventures LLC
6.10%
其他
52.83%
股東類型
持股股東
佔比
Individual Investor
17.49%
Venture Capital
15.29%
Corporation
9.18%
Investment Advisor
6.92%
Hedge Fund
6.10%
其他
45.02%

機構持股

更新時間: 4月21日 週二
更新時間: 4月21日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2026Q2
3
19.32M
29.05%
+19.32M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
暫無數據
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI